

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 91092

Title: Britanin – a beacon of hope against gastrointestinal tumors?

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05447678

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Poland

Manuscript submission date: 2023-12-21

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2024-01-17 05:09

Reviewer performed review: 2024-01-22 01:20

Review time: 4 Days and 20 Hours

| | |
|---|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Novelty of this manuscript | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty |
| Creativity or innovation of this manuscript | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation |

| | |
|---|--|
| Scientific significance of the conclusion in this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
| | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

The authors introduced us the natural compound britanin, a bioactive sesquiterpene lactone, having powerful anti-tumor activity in several tumors via multiple signal pathways. As mentioned by the authors, the compound britanin could also enhance T cell activity by inhibiting PD-L1 transcription. In the end of this review, the authors also emphasized the possibility of britanin as a promising anti-cancer drug in gastrointestinal carcinoma in future. In my opinion, one or two diagrams should be supplemented to describe the mechanism of britanin suppressing tumors. Also, the content of this review should be much more closed to the title. As my advice, the authors could try to answer the question why do you think britanin can be used as a promising anti-tumor drug in gastrointestinal tumor.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 91092

Title: Britanin – a beacon of hope against gastrointestinal tumors?

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05382317

Position: Peer Reviewer

Academic degree: FRCS (Hon), MD

Professional title: Doctor, Surgeon

Reviewer's Country/Territory: China

Author's Country/Territory: Poland

Manuscript submission date: 2023-12-21

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2024-01-18 15:36

Reviewer performed review: 2024-01-28 16:09

Review time: 10 Days

| | |
|---|--|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Novelty of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty |
| Creativity or innovation of this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation |

| | |
|---|--|
| Scientific significance of the conclusion in this manuscript | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous |
| | Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS

This minireview compiled and discussed the advance in Britanin in gastrointestinal tumors and outlined new research directions for Britanin in gastrointestinal research using data from outside scope of the digestive system. These contribute to the development of Britanin as a novel anti-tumor chemotherapeutic agent.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 91092

Title: Britanin – a beacon of hope against gastrointestinal tumors?

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05447678

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Poland

Manuscript submission date: 2023-12-21

Reviewer chosen by: Ze-Mao Gong

Reviewer accepted review: 2024-03-08 03:07

Reviewer performed review: 2024-03-08 03:13

Review time: 1 Hour

| | |
|---------------------------------|---|
| Scientific quality | <input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish |
| Language quality | <input checked="" type="radio"/> Grade A: Priority publishing <input type="radio"/> Grade B: Minor language polishing <input type="radio"/> Grade C: A great deal of language polishing <input type="radio"/> Grade D: Rejection |
| Conclusion | <input checked="" type="radio"/> Accept (High priority) <input type="radio"/> Accept (General priority) <input type="radio"/> Minor revision <input type="radio"/> Major revision <input type="radio"/> Rejection |
| Peer-reviewer statements | Peer-Review: <input checked="" type="radio"/> Anonymous <input type="radio"/> Onymous Conflicts-of-Interest: <input type="radio"/> Yes <input checked="" type="radio"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The authors have modified this manuscript according to the suggestions and I agree to accept it.